ZUPLENZ for chemotherapy-induced nausea and vomiting (CINV)

CINV occurs in up to 90% of patients undergoing moderately emetogenic chemotherapy10

In moderately emetogenic chemotherapy1,7

  • 61% of patients receiving moderately emetogenic chemotherapy experienced no emetic episodes during the study period1,7
  • 5-HT3 receptor antagonists are recommended by major guidelines for management of CINV10-13


Important Safety Information

  • The most common adverse drug reactions (≥5%) reported in clinical trials of patients receiving ondansetron 8 mg twice daily for prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy compared to placebo were headache (24% vs 13%), malaise/fatigue (13% vs 2%), constipation (9% vs <1%), and diarrhea (6% vs 4%)

ZUPLENZ delivers the trusted efficacy of ondansetron in a quick-dissolving film

  • Packaged for discreet, on-the-go use
  • Can be taken with or without water1
  • Dissolves rapidly in the mouth in about 10 seconds14-16
  • Is nonsedating1
  • Can be taken anytime, anywhere

ASCO=American Society of Clinical Oncology.
NCCN=National Comprehensive Cancer Network.
MASCC=Multinational Association of Supportive Care in Cancer.
ASHP=American Society of Health-System Pharmacists.

*Not an actual patient.

For the prevention of postoperative, highly and moderately emetogenic cancer chemotherapy-induced, and radiotherapy-induced nausea and vomiting.

The concomitant use of apomorphine with ondansetron is contraindicated based upon reports of profound hypotension and loss of consciousness.

Patients known to have hypersensitivity to ondansetron and to other selective 5-HT3 receptor antagonists should not take ZUPLENZ. Hypersensitivity reactions, including anaphylaxis and bronchospasm, have been reported. Rarely and predominantly with intravenous ondansetron, transient electrocardiographic changes, including QT interval prolongation, have occurred.

The use of ZUPLENZ in patients following abdominal surgery or in patients with chemotherapy-induced nausea and vomiting may mask a progressive ileus and/or gastric distension. ZUPLENZ does not stimulate gastric or intestinal peristalsis and should not be used instead of nasogastric suction.

The most common adverse drug reactions (≥5%) reported in clinical trials of patients receiving ondansetron for prevention of nausea and vomiting associated with cancer chemotherapy or radiotherapy were headache, malaise/fatigue, constipation, and diarrhea. For postoperative nausea and vomiting, headache occurred at a rate significantly different from placebo.

ZUPLENZ is available by prescription only. Please click here for complete Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch, or call 1-800-FDA-1088.

For more information about ZUPLENZ, call 1-888-834-7800.